NCT03668418: xenoZ

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Status unknown Last updated 12 September 2018

What this trial tests

trial testing Fluorouracil in Liver Cancer in 120 participants. Status unknown.

Timeline

1 June 2018

Primary endpoint
31 May 2021

31 May 2022

Quick facts

Lead sponsor	University of Pisa
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 June 2018
Primary completion	31 May 2021
Estimated completion	31 May 2022
Sites	1 location across Italy

Drugs / interventions tested

• Fluorouracil — full drug profile →
• Lederfolin
• Oxaliplatin (Oxaliplatin) — full drug profile →
• Irinotecan
• Docetaxel
• Cisplatin (cisplatin) — full drug profile →
• Epirubicin (EPIRUBICIN) — full drug profile →
• Gemcitabine (gemcitabine) — full drug profile →
• Nab paclitaxel

Conditions studied

• Liver Cancer — all drugs for Liver Cancer →
• Pancreatic Cancer — all drugs for Pancreatic Cancer →
• Gastric Cancer — all drugs for Gastric Cancer →
• Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

University of Pisa

Who can join

18 and older, any sex, with Liver Cancer or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study consists in a co-clinical trial by using zebrafish embryos. Specifically, an observational prospective clinical trial on patients operated of epato-biliar-pancreatic cancers and gastro-intestinal cancers undergoing a chemotherapy treatment will be run concurrently to an animal trial on zebrafish embryos xenotransplanted with patient cancer cells in order to demonstrate that zebrafish model is able to predict the therapeutic regimen with the best efficacy for each patient.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Zebrafish patient avatars in cancer biology and precision cancer therapy.
   Fazio M, Ablain J, Chuan Y, Langenau DM, et al · · 2020 · cited 153× · PMID 32251397 · DOI 10.1038/s41568-020-0252-3
2. A Model of a Zebrafish Avatar for Co-Clinical Trials.
   Usai A, Di Franco G, Colucci P, Pollina LE, et al · · 2020 · cited 48× · PMID 32183229 · DOI 10.3390/cancers12030677
3. Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.
   Durinikova E, Buzo K, Arena S. · · 2021 · cited 46× · PMID 34090508 · DOI 10.1186/s13046-021-01981-z
4. Patient-derived cancer models: Valuable platforms for anticancer drug testing.
   Genta S, Coburn B, Cescon DW, Spreafico A. · · 2022 · cited 25× · PMID 36033445 · DOI 10.3389/fonc.2022.976065
5. Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.
   Miserocchi G, Spadazzi C, Calpona S, De Rosa F, et al · · 2022 · cited 24× · PMID 35743639 · DOI 10.3390/jpm12060854
6. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine.
   Di Franco G, Usai A, Funel N, Palmeri M, et al · · 2020 · cited 22× · PMID 32550755 · DOI 10.3748/wjg.v26.i21.2792
7. Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients.
   Di Franco G, Usai A, Piccardi M, Cateni P, et al · · 2022 · cited 21× · PMID 35884780 · DOI 10.3390/biomedicines10071474
8. Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes.
   Al-Hamaly MA, Turner LT, Rivera-Martinez A, Rodriguez A, et al · · 2023 · cited 20× · PMID 36768609 · DOI 10.3390/ijms24032288